Profile

Scott Boitano

Physiology

Full Page

Overview

Research

Collaboration(39)

Page 1 of 8

Grants(20)

A Role for Pharmaceutical Control of Protease-activated Receptor-2 for the Treatment of Asthma
Active·2024·$358.3K / $716.7K·
External
Principal Investigator (PI)
pharmaceutical control, protease-activated receptor-2, asthma treatment, role of protease, drug therapy
Development of Small Molecule Antagonists of PAR2 for Oral Treatment of Asthma
Active·2023·$57.9K / $154.4K·
External
Principal Investigator (PI)
asthma, drug development, small molecule, oral treatment
Protease-activated-receptor-2 Antagonists for Treatment of Migraine Pain
Active·2023·$80.7K·
External
Principal Investigator (PI)
migraine, pain, protease, antagonists, treatment
Development of SP-A-Derived Peptidomimetics for the Treatment of Asthma - Phase II
Active·2022·$510.6K / $1M·
External
Principal Investigator (PI)
peptidomimetics, asthma, sp-a-derived, treatment, development
Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma
2024·$661K / $251.8K·
External
Principal Investigator (PI)
pharmacokinetics, asthma treatment, efficacy, aerosolized delivery, par2 antagonist

Page 1 of 4

Publications(47)

Recent

β-Arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation

2022

β-arrestin-biased, proteinase-activated receptor-2, antagonist c781, allergen-induced airway hyperresponsiveness, inflammation

Development of a Novel Mouse Model of Menopause-associated Asthma

2022

mouse models, menopause, asthma, novel model, hormonal changes

C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 PAR2) Displays in vivo Efficacy Against Protease-Induced Pain in Mice

2022

pain, protease, antagonist, β-arrestin, receptor-2

Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression

2022

airway inflammation, epithelial signaling, protease-activated receptor-2, allergen-induced responses, respiratory allergy

A Role for Protease Activated Receptor Type 3 PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist

2021

pain, neuroscience, peptide, receptor, drug development

Novel lipidated agonists and antagonists to protease-activated receptor 2 PAR2)

2021

lipidated compounds, protease-activated receptor-2, agonists, antagonists, novel compounds

Novel proteinase-activated receptor-2 PAR2) antagonist C391 inhibits Alternaria-induced human airway epithelial signaling in vitro and asthma indicators in acute exposure murine models

2021

proteinase-activated receptor-2 (par2), asthma, airway epithelial signaling, alternaria-induced, murine models

Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.

2021

airway inflammation, epithelial signaling, protease-activated receptor-2, allergic response, fungal-induced inflammation

Myeloid-associated differentiation marker is a novel SP-A-associated transmembrane protein whose expression on airway epithelial cells correlates with asthma severity

2021

myeloid differentiation, sp-a protein, airway epithelial cells, asthma severity, transmembrane proteins

The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain

2020

cellular, protease, pain, receptor, affective

People

Profile

Scott Boitano

Collaboration(39)

Walter Klimecki

Kenneth Knox

Fernando Martinez

Jefferey Burgess

William Montfort

Grants(20)

A Role for Pharmaceutical Control of Protease-activated Receptor-2 for the Treatment of Asthma

Development of Small Molecule Antagonists of PAR2 for Oral Treatment of Asthma

Protease-activated-receptor-2 Antagonists for Treatment of Migraine Pain

Development of SP-A-Derived Peptidomimetics for the Treatment of Asthma - Phase II

Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma

Publications(47)

β-Arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation

Development of a Novel Mouse Model of Menopause-associated Asthma

C781, a β-Arrestin Biased Antagonist at Protease-Activated Receptor-2 PAR2) Displays in vivo Efficacy Against Protease-Induced Pain in Mice

Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression

A Role for Protease Activated Receptor Type 3 PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist

Novel lipidated agonists and antagonists to protease-activated receptor 2 PAR2)

Novel proteinase-activated receptor-2 PAR2) antagonist C391 inhibits Alternaria-induced human airway epithelial signaling in vitro and asthma indicators in acute exposure murine models

Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.

Myeloid-associated differentiation marker is a novel SP-A-associated transmembrane protein whose expression on airway epithelial cells correlates with asthma severity

The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain